Literature DB >> 32311931

The correlation of neuropsychological evaluation with 11C-PiB and 18F-FC119S amyloid PET in mild cognitive impairment and Alzheimer disease.

Su Yeon Park1, Byung Hyun Byun2, Byung Il Kim2, Sang Moo Lim2, In Ok Ko3, Kyo Chul Lee3, Kyeong Min Kim3, Yu Kyeong Kim4, Jun-Young Lee5, Seon Hee Bu6, Jung Hwa Kim6, Dae Yoon Chi7,8, Jeong Ho Ha1.   

Abstract

For the diagnosis of mild cognitive impairment (MCI) and Alzheimer disease (AD), variable neuroimaging and neuropsychological tests have been used. We aimed to evaluate the correlation of neuropsychological domain with new amyloid positron emission tomography (PET) study and to validate the availability of new PET tracer.We enrolled 20 patients who underwent C-PiB-PET/CT, new PET tracer F-FC119S PET/CT from November, 2014 to July, 2015. Among them, 10 patients were diagnosed with AD and 10 patients with MCI. The current version of Seoul Neuropsychological Screening Battery (SNSB) II was performed for cognitive evaluation. Each parameter of SNSB was compared between 2 patient groups. Spearman correlation analysis between value of SNSB domain and standardized uptake value ratio (SUVR) of PET was also performed.The AD group presented significant poor z-score in Korean-Boston Naming Test(K-BNT) (P = .01),copy score of Rey Complex Figure Test (RCFT) (P = .049), immediate (P = .028)and delayed memory of Seoul Verbal Learning Test (SVLT) (P = .028), recognition of RCFT (P = .004), "animal" of Controlled Oral Word Association Test (COWAT) (P = .041), color reading of Korean-Color Word Stroop test (K-CWST) (P = .014), and Digit Symbol Coding (DSC) (P = .007) compared with MCI group. That means, except attention domain, all other cognitive domains were relatively impaired in AD compared with MCI. In correlation analysis, we found that poor performances on copy score of RCFT in MCI groups were associated with great beta amyloid burden in frontal area in both C-PiB-PET/CT and F-FC119S PET/CT. In AD group, F-FC119S PET presented more extensive correlation in each cognitive domain with multiple cortical areas compared with C-PiB-PET.The degree of amyloid burden assessed on F-FC119S PET was significantly correlated with neuropsychological test in AD, and also MCI patients. The combination of neuropsychological evaluation with novel F-FC119S PET/CT can be used for valid biomarker for MCI and AD.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32311931      PMCID: PMC7220040          DOI: 10.1097/MD.0000000000019620

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


Introduction

Alzheimer disease (AD) is the most common type of dementia, and progressive neurodegenerative disease characterized by cognitive dysfunction and daily activity impairment.[ Definite diagnosis of AD could only be made by post-mortem neuropathological analysis. The pathologic hallmarks of AD have been known to be deposition of neurofibrillary tangles and beta amyloid (Aß) plaques.[ On the contrary, mild cognitive impairment (MCI) is characterized by cognitive dysfunction with relatively preserved activities of daily living and without dementia .[ MCI patients tend to progress to AD at a rate of 10% to 15% per year,[ but some of the patients still remain stable.[ Many studies have been described about risk factors for dementia, such as age, sex, hippocampus, or medial temporal area reduction[; however, the risk factors for this progression and definite clinical predictive markers have not been fully evaluated. At present, dementia has become a major healthcare problem. One meta-analysis of epidemiological studies of dementia in South Korea showed that the prevalence of AD was 5.7% and vascular dementia was 2.1%, indicating that AD was the most prevalent type in Korea.[ As dementia inevitably leads to significant increase in economic and social burden, early diagnosis and disease modification of high-risk MCI would be important in clinical practice. Until now, the variable neuroimaging and neuropsychological tests have been studied for the diagnosis and prediction of progress in MCI and AD patients. Cognitive evaluation using neuropsychological test has performed a crucial role in diagnosis of dementia and MCI. It is useful in differentiation of MCI subtypes and is cost-effective in diagnosis of AD.[ The Seoul Neuropsychological Screening Battery (SNSB) is one of the most commonly used neuropsychological test in South Korea.[ This battery is composed of 5 cognitive domains: attention, language, memory, visuospatial, and frontal/executive functions.[ It is a reliable and valid test which may take 1.5 to 2 hours to complete. The current version of SNSB (SNSB II) analyzes the 45 to 90-year-old criteria. It based on nationwide large Korean sample (1100 people), and the continuous data values were converted to z-score which were standardized with educational level and age.[ A z-score <−1 presents an abnormal value by SNSB II criteria.[ Additionally, SNSB II includes Korean-Mini Mental State Examination (K-MMSE), Clinical Dementia Rating (CDR), Korean-Instrumental Activities of Daily Living (K-IADL), and Barthel-Activities of Daily Living (B-ADL). In addition to neuropsychological test, imaging of brain Aß using positron emission tomography (PET) also has been widely used for early identification of AD, and differentiation AD from non-AD patients.[11C-Pittshurgh compound B (PiB) is the first amyloid imaging, which showed significant retention in brain of AD patients.[ Also, 11C-PiB-PET appeared to positive in 50% to 60% of MCI subjects.[ However, short radioactive half-life has been the major limitation of 11C-PiB PET, preventing its widespread use, and therefore, other 18F-labeled PET tracers have been developed.[ Among them, 18F-FC119S was introduced as a new Aß PET tracer which showed excellent binding affinity for synthetic Aß1–42 aggregates and rapid clearance in preclinical study.[ In the previous study with 10 MCI and 10 AD patients, we showed that the cortical uptakes of 18F-FC119S were significantly correlated with those of 11C-PiB-PET/CT, and so this new PET tracer can be effectively available for Aß imaging with longer radioactive half-lives.[ However, except for imaging comparison of 18F-FC119S and 11C-PiB-PET, comprehensive analysis of neuropsychological tests in MCI and AD patients has not been performed. For the widespread clinical application of novel PET tracer, correlation between novel PET tracer and current standard neuropsychological tests need to be defined. This study aimed to evaluate the correlation between neuropsychological domain and new amyloid PET study in patients with MCI and AD, and to assess the potential as useful imaging biomarker for extensive clinical application.

Methods

Subjects

In the previous study,[ 28 healthy controls, 10 patients with MCI, and 10 patients with AD were included. Among them, the datasets of 10 MCI and 10 AD patients were analyzed for present study. The inclusion criteria for MCI were as follows: aged 55 years or older; had objective cognitive impairment; and no disability in their daily activities.[ The inclusion criteria for AD were as follows: aged 55 years or older with definite AD or probable AD according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer Disease and Related Disorders Association Alzheimer criteria.[ The subjects with severe medical illnesses or other neurological disease were excluded. All subjects underwent a neuropsychological evaluation using SNSB II and were subjected to 11C-PiB-PET/CT and 18F-FC119S PET/CT. This study was approved by the Institutional Review Board of KIRAMS.

Neuropsychological assessment

The current version of SNSB (SNSB II) was used for neuropsychological evaluations. These batteries involve attention, language, memory, visuospatial, and frontal/executive functions.[ Domain of memory function is composed of Seoul Verbal Learning Test (SVLT) (immediate, 20 minutes delayed recall, recognition) and the Rey Complex Figure Test (RCFT) (immediate, 20 minutes delayed recall, recognition). Domain of frontal/executive function includes motor impersistence, contrasting program, go-no-go, fist-edge-palm, alternating hand movement, alternating square and triangle, luria loop, Controlled Oral Word Association Test (COWAT), Korean-Color Word Stroop test (K-CWST), Digit Symbol Coding (DSC), and Korean-Trail Making test. Domain of language function includes Korean-Boston Naming Test (K-BNT), right-left orientation, and calculation. Domain of attention function includes Digit Span Test (DST), letter cancellation, and vigilance test. Domain of visuospatial function is composed of Clock Drawing Test (CDT) and RCFT. The continuous raw data values were converted to z-score, which were standardized with educational level and age. We analyzed these z-scores because the z-scores are elaborately defined and enable to minimize the effects of illiteracy.[ Thus z-score allows precise comparative analysis between the various subjects. Additionally, K-MMSE and CDR were also evaluated.

Neuroimaging analysis

All patients underwent 11C-PiB-PET/CT and 18F-FC119S PET/CT within 3 months after the neuropsychological test.[ Quantitative PET image analysis was performed to obtain the standardized uptake value (SUV) for each brain region including frontal cortex, temporal cortex, parietal cortex, occipital cortex, anterior cingulate, posterior cingulated, and global SVUR.[ SUV ratios (SUVRs) were calculated using cerebellar cortex as a reference region. The detail protocols were described in previous study.[ All patients underwent 11C-PiB-PET/CT and 18F-FC119S PET/CT within 3 months after the neuropsychological test.[ Quantitative PET image analysis was performed to obtain the standardized uptake value (SUV) for each brain region including frontal cortex, temporal cortex, parietal cortex, occipital cortex, anterior cingulate, posterior cingulated, and global SVUR.[ SUV ratios (SUVRs) were calculated using cerebellar cortex as a reference region. The detail protocols were described in previous study.[

Statistical analysis

Demographics and clinical data of MCI and AD patients were compared using Mann-Whitney U test. Neuropsychological data of SNSB II adjusted by age and educational level were compared between MCI and AD patients using Mann-Whitney U test. The correlation between neuropsychological tests and SUVR of 11C-PiB-PET/CT and 18F-FC119S PET/CT was evaluated using Spearman correlation in each MCI and AD groups. Commercially available software program (SPSS ver 21.0, SPSS, Chicago, IL) was used for all analyses. The level of statistical significance was at P < .05.

Results

Clinical and neuropsychological results

Ten patients with MCI and 10 patients with AD were evaluated in this study. Demographic characteristics are summarized in Table 1. Age and sex showed no significant difference between MCI and AD patients. AD patients had significantly poorer K-MMSE and CDR than MCI patients. To analyze the differences in cognition between MCI and AD subjects, the comparison of neuropsychological data was performed. The values were presented as z-score. AD groups presented significant poorer z-score in K-BNT (P = .01), copy score of RCFT (P = .049), immediate (P = .028), and delayed memory of SVLT (P = .028), recognition of RCFT (P = .004), “animal” of COWAT (P = .041), and color reading of K-CWST (P = .014) and DSC (P = .007) (Table 2).
Table 1

Demographic and clinical data of MCI and AD subjects.

Table 2

Neuropsychological data of MCI and AD subjects.

Demographic and clinical data of MCI and AD subjects. Neuropsychological data of MCI and AD subjects.

Correlations between the neuropsychological domain and PET

Table 3 showed correlation of neuropsychological domain with 11C-PiB-PET/CT in patients with MCI and AD. In MCI groups, poor copy score of RCFT was associated with high SUVR in frontal cortex (Fig. 1). In AD groups, poor value of copy time of RCFT was associated with high SUVRs in frontal, temporal, parietal, occipital, anterior cingulate, posterior cingulate, and global area. Also, recognition of SVLT and RCFT showed negative correlation with SUVRs of frontal cortex in AD patients. Also, immediate memory of RCFT and recognition of SVLT showed negative correlation with SUVRs of global area in AD groups. Significant correlations were not observed with other neuropsychological values.
Table 3

Correlations between SUVRs of 11C-PiB and neuropsychological tests in MCI and AD patients.

Figure 1

Scatter-plot shows significant negative correlation between SUVR of 11C-PiB-PET on frontal lobe and copy score of RCFT.

Correlations between SUVRs of 11C-PiB and neuropsychological tests in MCI and AD patients. Scatter-plot shows significant negative correlation between SUVR of 11C-PiB-PET on frontal lobe and copy score of RCFT. Table 4 showed correlation of neuropsychological domain in SNSB with 18F-FC119S PET/CT. In MCI groups, copy score of RCFT showed significant negative correlation with SUVR of frontal cortex (Fig. 2), which presents similar results with 11C-PiB-PET/CT. The poor value of tests including K-BNT, immediate memory of RCFT, “⌝” of COWAT were also associated with high SUVRs in frontal cortex in MCI. In AD group, 18F-FC119S PET presented more extensive correlations of cognitive domains with many cortical areas including frontal, temporal, parietal, anterior cingulate, and posterior cingulate areas compared with 11C-PiB-PET.
Table 4

Correlations between SUVRs of 18F-FC119S and neuropsychological tests in MCI and AD patients.

Figure 2

Scatter-plot shows significant negative correlation between SUVR of 18F-FC119S-PET on frontal lobe and copy score of RCFT.

Correlations between SUVRs of 18F-FC119S and neuropsychological tests in MCI and AD patients. Scatter-plot shows significant negative correlation between SUVR of 18F-FC119S-PET on frontal lobe and copy score of RCFT.

Discussion

This study was conducted to explore association between cognitive function and anatomical lesion on new amyloid PET, and to assess the potential as useful biomarker for extensive clinical application in MCI and AD patients. To our knowledge, this is the first study to analyze the correlation between novel 18F-FC119S PET and detail cognitive function. Our previous study suggested that18F-FC119S might be appropriate for imaging Aß.[ The uptake of 18F-FC119S was significantly correlated with that of 11C-PiB-PET/CT. Although 18F-FC119S has shown the potential for imaging biomarker of MCI and dementia, correlation between this new PET tracer and cognitive function has yet to be determined. We present here the correlation between novel PET tracer and current standard neuropsychological tests in Korea for widespread clinical application based on the results of previous study. In our study, the new Aß PET tracer, 18F-FC119S PET, showed similar correlation with 11C-PiB-PET in several cognitive tests, and uptakes in amyloid PET was significantly correlated with cognitive domain in neuropsychological test. Many neuropsychological tests contribute to the detection and differentiation of AD from normal aging or other types of dementia and MCI. In our neuropsychological analysis, AD patients had significantly poorer K-MMSE and CDR than MCI patients. The comparison of subsets of SNSB showed that language (K-BNT), visuospatial (copy score of RCFT), memory (immediate and delayed memory of SVLT, recognition of RCFT), frontal/executive (COWAT [animal], K-CWST [color reading], DSC) domains were significantly impaired in the AD group compared with the MCI group; that is, except attention, all other cognitive domains were relatively impaired in the AD group. Many studies have presented that AD patients showing impaired episodic memory may be due to ineffective consolidation.[ Also, patients with AD present visuospatial dysfunction even in early preclinical stage and mild AD.[ Early-onset AD patients performed poorly on forward, backward digit, visual spans, visual counting, and Rey complex figure test, which suggested poor attention and visuospatial function.[ Our results are in agreement with these reports which showed specific cognitive dysfunction in AD patients.[ Neuropsychological dysfunction in MCI is also common. One meta-analysis showed that verbal memory and many language testes had high predictive accuracy in predicting progression from MCI to AD, and executive functions and visual memory had better specificity.[ In correlation analysis using 11C-PiB-PET, we found that in MCI patients, poor performance on copy score of RCFT was associated with great Aß burden in frontal area. The new Aß PET tracer, 18F-FC119S PET, showed similar correlation with 11C-PiB-PET in this cognitive test. That means, in MCI patients, the visuospatial function was commonly associated with degree of Aß burden in frontal area. In AD groups, copy time of RCFT showed negative correlation with SUVRs in frontal, temporal, parietal, occipital, anterior cingulate, posterior cingulate, and global area using 11C-PiB-PET. However, 18F-FC119S PET presented more extensive correlations of each cognitive domain with cortical areas in AD compared with 11C-PiB-PET. However, in advanced stage of dementia, specific cognitive domain boundaries can be obscured, so neuropsychological study is most useful in early stage of disease.[ There have been many studies about correlation of neuropsychological characteristics with brain imaging including PET, MR, and single-photon emission computed tomography (SPECT) in MCI and AD patients. One study reported that amnestic MCI had early amyloid deposition in precuneus, frontal, and posterior cingulate areas in 18F-AV-45 PET.[ MCI patients showed poor visuospatial memory and atrophy in frontal and mediotemporal areas compared with normal group.[ The low blood flow of the left frontal area and cognitive test of orientation in MCI patients were good predictive factors for risk of developing dementia.[ It is not simple to decide which area performs dominant role in cognition because complex brain networks are involved in cognitive function. Because the amyloid burden of MCI and AD patients can affect the neuropsychological function, the degree of cortical uptake can be predictive factor of the severity of cognitive dysfunction. This study has some limitations. The sample size of patients was small and diagnosis of patients was performed by clinical criteria. Also, we did not subdivide the MCI group into amnestic and nonamnestic MCI. Future studies including a larger number of patients in multicenter could be helpful to verify our results.

Conclusions

In conclusions, the degree of amyloid burden assessed on 18F-FC119S PET was significantly correlated with neuropsychological test in AD as well as MCI patients, and which showed similar results with 11C-PiB-PET. So, considering good clinical utility of new Aß tracer, 18F-FC119S would be a candidate PET imaging biomarker in MCI and AD.

Author contributions

Conceptualization: Su Yeon Park. Data curation: Byung Hyun Byun. Formal analysis: Francesco Mantia. Investigation: Byung Il Kim, In Ok Ko, Kyo Chul Lee, Kyeong Min Kim, Yu Kyeong Kim, Dae Yoon Chi. Supervision: Sang Moo Lim. Resources: Jun-Young Lee, Seon Hee Bu, Jung Hwa Kim. Writing – review & editing: Jeong Ho Ha.
  22 in total

1.  Brain amyloid imaging.

Authors:  Christopher C Rowe; Victor L Villemagne
Journal:  J Nucl Med       Date:  2011-09-14       Impact factor: 10.057

Review 2.  Mild cognitive impairment as a diagnostic entity.

Authors:  R C Petersen
Journal:  J Intern Med       Date:  2004-09       Impact factor: 8.989

3.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

4.  Visuospatial memory and neuroimaging correlates in mild cognitive impairment.

Authors:  Micaela Mitolo; Simona Gardini; Fabrizio Fasano; Girolamo Crisi; Annalisa Pelosi; Francesca Pazzaglia; Paolo Caffarra
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

5.  Synthesis and evaluation of 6-(3-[(18)F]fluoro-2-hydroxypropyl)-substituted 2-pyridylbenzothiophenes and 2-pyridylbenzothiazoles as potential PET tracers for imaging Aβ plaques.

Authors:  Byoung Se Lee; So Young Chu; Hye Rim Kwon; Chansoo Park; Uthaiwan Sirion; Damian Brockschnieder; Thomas Dyrks; Seung Jun Oh; Jae Seung Kim; Dae Yoon Chi
Journal:  Bioorg Med Chem       Date:  2016-03-19       Impact factor: 3.641

6.  Age at onset and visuocognitive disturbances in Alzheimer disease.

Authors:  M Fujimori; T Imamura; H Yamashita; N Hirono; Y Ikejiri; T Shimomura; E Mori
Journal:  Alzheimer Dis Assoc Disord       Date:  1998-09       Impact factor: 2.703

Review 7.  Prevalence and trends of dementia in Korea: a systematic review and meta-analysis.

Authors:  You Joung Kim; Ji Won Han; Yoon Seop So; Ji Young Seo; Ka Young Kim; Ki Woong Kim
Journal:  J Korean Med Sci       Date:  2014-07-11       Impact factor: 2.153

8.  Anatomical Correlates of Neuropsychological Deficits Among Patients With the Cerebellar Stroke.

Authors:  Min A Shin; Oak Tae Park; Joon-Ho Shin
Journal:  Ann Rehabil Med       Date:  2017-12-28

9.  Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients.

Authors:  Byung Hyun Byun; Byung Il Kim; Su Yeon Park; In Ok Ko; Kyo Chul Lee; Kyeong Min Kim; Yu Kyeong Kim; Jun-Young Lee; Seon Hee Bu; Jung Hwa Kim; Dae Yoon Chi; Jeong Ho Ha; Sang Moo Lim
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

10.  Regional amyloid deposition in amnestic mild cognitive impairment and Alzheimer's disease evaluated by [18F]AV-45 positron emission tomography in Chinese population.

Authors:  Kuo-Lun Huang; Kun-Ju Lin; Ing-Tsung Hsiao; Hung-Chou Kuo; Wen-Chuin Hsu; Wen-Li Chuang; Mei-Ping Kung; Shiaw-Pyng Wey; Chia-Ju Hsieh; Yau-Yau Wai; Tzu-Chen Yen; Chin-Chang Huang
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

View more
  1 in total

1.  Repeatable battery for the assessment of neuropsychological status and its relationship to biomarkers of Alzheimer's disease.

Authors:  Kevin Duff; Kayla R Suhrie; Dustin B Hammers; Ava M Dixon; Jace B King; Vincent Koppelmans; John M Hoffman
Journal:  Clin Neuropsychol       Date:  2021-10-29       Impact factor: 4.373

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.